Condition: ALS - Amyotrophic Lateral Sclerosis · Sponsor: PathMaker Neurosystems Inc.
Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded number of individuals with ALS. CALM will gather additional preliminary evidence of clinical safety and potential effectiveness in this patient population with a longer follow-up period and additional secondary endpoints in a single-arm study prior to commencing a larger sham-controlled pivotal trial.
This description comes directly from the study's public registry record.
Seward Rutkove (Clinical Site PI), M.D. · 617-667-3069 · mhemme@bidmc.harvard.edu
Nader Yaghoubi (Study PI), M.D., Ph.D. · 617-535-7696 · nyaghoubi@pmneuro.com
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06649955